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Trematode infections such as schistosomiasis and fascioliasis cause significant morbidity in an 
estimated 250 million people worldwide and the associated agricultural losses are estimated at more 
than US$ 6 billion per year. Current chemotherapy is limited. Triosephosphate isomerase (TIM), an 
enzyme of the glycolytic pathway, has emerged as a useful drug target in many parasites, including 
Fasciola hepatica TIM (FhTIM). We identified 21 novel compounds that selectively inhibit this enzyme. 
Using microscale thermophoresis we explored the interaction between target and compounds and 
identified a potent interaction between the sulfonyl-1,2,4-thiadiazole (compound 187) and FhTIM, 
which showed an ic50 of 5 µM and a Kd of 66 nM. In only 4 hours, this compound killed the juvenile form 
of F. hepatica with an ic50 of 3 µM, better than the reference drug triclabendazole (TCZ). Interestingly, 
we discovered in vitro inhibition of FhTIM by TCZ, with an IC50 of 7 µM suggesting a previously 
uncharacterized role of FhTIM in the mechanism of action of this drug. Compound 187 was also active 
against various developmental stages of Schistosoma mansoni. The low toxicity in vitro in different cell 
types and lack of acute toxicity in mice was demonstrated for this compound, as was demonstrated 
the efficacy of 187 in vivo in F. hepatica infected mice. Finally, we obtained the first crystal structure of 
FhTIM at 1.9 Å resolution which allows us using docking to suggest a mechanism of interaction between 
compound 187 and TIM. In conclusion, we describe a promising drug candidate to control neglected 
trematode infections in human and animal health.
Trematode infections are a major cause of human disability and mortality in many developing countries, and 
remain one of the most important challenges for medicine in the 21st century1–3. An estimated 250 million people 
worldwide suffer these infections. Moreover, the Fasciola and Schistosoma parasites infect cattle, sheep and other 
animals of agricultural importance with estimated agricultural losses of more than US$ 6 billion per year4. In spite 
of their morbidity and economic impact, neither disease is of sufficient pharmaceutical industry interest for the 
development of new drugs, such that anthelmintic therapy relies precariously on just two drugs that were devel-
oped over 40 years ago: triclabendazole (TCZ) for fascioliasis and praziquantel (PZQ) for schistosomiasis1,2. The 
over-reliance on TCZ to treat sheep and, to a lesser extent, cattle, has resulted in selection for flukes resistant to 
TCZ. For PZQ, although clinically-relevant resistance has yet to emerge, resistance has been reported on occasion 
in the field and in various experimental settings5–7.
An important characteristic in the metabolism of trematode parasites is their dependence on glycolysis as 
an energy source for survival8. Thus, enzymes in the glycolytic pathway are attractive targets in the search for 
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new small molecules chemotherapies9,10. One enzyme, triosephosphate isomerase (TIM; EC 5.3.1.1), is of par-
ticular interest as an anthelmintic target8. TIM catalyzes the isomerization of glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate in the fifth step of the glycolytic pathway11. It also has moonlighting functions, as 
it is found differently expressed in many types of cancer, it participates in the regulation of the cell cycle, func-
tion as an auto-antigen and in the evasion of the immune response, as a virulence factor in some organisms12. 
Structurally, most of the known TIMs are homodimers, each monomer consisting of eight parallel β-strands 
surrounded by eight α-helices that, together, form a typical “TIM barrel” fold. The interface between mono-
mers occupies a significant portion of the molecular surface area of each monomer, approximately 1500 Å2 13–15. 
Because TIM is active only in its dimeric form, small molecules that engage the interface may interfere with 
proper enzyme function16.
Encouraged by the fact that only 50% of the residues involved in the dimer interface are conserved between 
trematode TIMs and their human ortholog17, we aimed to identify molecules that specifically engage the parasite 
TIM interface. Accordingly, using 340 in-house compounds, we screened in vitro recombinant FhTIM for low 
micromolar inactivators. With the best compounds, we performed selectivity assays (using mammalian TIMs) 
and preclinical studies (toxicology in mammalian cells and in mice). We evaluated their efficacy in vivo in mice 
infected with F. hepatica and perform X-Ray and docking studies to elucidate the mechanism of inhibition.
Results
Screening FhTIM. We hypothesized that a TIM dimer interface inactivator would be a successful strat-
egy to identify molecules with selective antiparasitic activity18–20. Therefore, we selected 340 compounds from 
our in-house chemical collection and screened them against the isolated recombinant FhTIM. In this work, the 
screened chemotypes are represented in Fig. 1 (benzofuroxanes, furanes and thiophenes, 4-substituted-1,2,6-thi-
adiazines, quinoxaline 1,4-dioxides, phenazine 5,9-dioxides, furoxanes, imidazole N-oxides, indazoles and oth-
ers). Around 10% of the evaluated compounds were active with an IC50 <100 µM (concentration leading to at 
least 50% inhibition). Most of the families possess at least one active compound, except for the twenty evaluated 
quinoxalines from which no active molecules were found. Those families with a high percentage of active deriv-
atives were the 4-substituted-1,2,6-thiadiazines, selenocompounds and phenazines, 60% (9/15), 100% (3/3) and 
67% (2/3) active, respectively. We found 30–40% of inactivators among the thiadiazines and their precursors, and 
the curcuminoids family (Supplementary Table 1S). We established an IC50 <50 µM as the cut-off for good activ-
ity (Table 1). Only one active compound belongs to the thiadiazole chemotype (compound 187, Fig. 1), which had 
Figure 1. Inhibition cascade for a screen of 340 small molecules with recombinant FhTIM. Structures of the 
best inhibitors are shown. Compounds are numbered according to Supplementary Table 1S. Three ranges of 
inhibitory activity were established: IC50 >100 µM (no activity, not shown), IC50 values between 50 and 100 µM 
(moderate activity) and IC50 <50 µM (good activity).
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Compound identifier Structure IC50 (µM) Kd (µM)
110 7 ± 1 nd*
114 25 ± 8 664 ± 25
115 8 ± 2 120 ± 12
116 5 ± 1 nd
121 50 ± 9 nd
128 5 ± 1 120 ± 10
1148 15 ± 5 nd
135 50 ± 8 nd
310 79 ± 7 nd
144 60 ± 2 nd
1134 45 ± 4 nd
187 4.0 ± 0.2 0.07 ± 0.01
1278 (TCZ) 7 ± 1 1000
482 30 ± 3 nd
183 25 ± 3 nd
1149 50 ± 6 nd
906 35 ± 4 nd
1254 50 ± 5 nd
1267 35 ± 2 nd
Table 1. IC50 values of the best TIM inactivators and experimental Kd values by MST. *nd. not determined.
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the greatest inhibition of the molecular target (Table 1). Interestingly, TCZ (compound 1278 in the collection) 
inhibited FhTIM with an IC50 of 7 µM (Table 1). In parallel, we performed MicroScale Thermophoresis (MST) 
with five representative molecules to evaluate their binding affinity. Among them, compound 187 showed the 
highest affinity for FhTIM with the lowest IC50 (4.0 ± 0.2).
Then we performed an in vitro selectivity assay of FhTIM as compared to human (HsTIM) and rabbit TIM as a 
representative ruminant animal21. The best FhTIM inhibitors, 110, 115, 128, 187 and TCZ, were inactive (<20% 
inhibition) against HsTIM and rabbit TIM at 100 µM.
In vitro and in vivo anti-parasite activity of the compounds. As a proof of concept, we tested the best 
FhTIM inactivators against F. hepatica and S. mansoni parasites. Also, we use compound 191 as a non-inhibitor 
which has a closely related structure to that of compound 187. Some compounds were able to kill 100% of the 
newly excysted juvenile (NEJ) F. hepatica within 4 to 48 h (Table 2 and Fig. 2). Also, some of the compounds that 
were active against NEJ markedly affected S. mansoni, notably compound 187, which, in the first 24 h, was lethal 
to somules, and decreased the motility of adults and the ability of their oral and ventral suckers to adhere to the 
floor of the culture dish well (Tables 2 and S2). In parallel, these compounds were assayed to characterize their 
non-specific toxicity against murine macrophages and bovine sperm. Both models are recommended by FDA 
as an in vitro prediction of toxicology22. We used fixed doses of 25 and 100 µM of compound to test against the 
Compound
F. hepatica S. mansoni 
somules severity 
score*
Toxicity 
mammalian 
cells**
IC50 
(µM)
incubation 
time (h)
906 7 ± 1 4 nd*** T
110 5 ± 2 30 0 T.
114 6.5 ± 0.6 4 4 (72 h) T
115 7 ± 2 72 4 (72 h) T
116 >50 72 Nd nd
128 10 ± 1 12 Nd T
1148 12 ± 2 4 0 nd
144 25 ± 5 72 4 (72 h) NT
1134 50 ± 6 72 Nd NT
187 3.0 ± 0.5 4 4 (24 h)## NT
1293# 50 48 Nd nd
1278 (TCZ) >50 72 Nd NT
Table 2. The activity of the best compounds against juvenile forms of F. hepatica and S. mansoni somules. 
*Severity score defined in Methods (S. mansoni: treatment of somules in vitro and adults ex vivo). **The 
selectivity index for the effect on the parasite vs. mammalian cells, NT represents an SI >10 when the toxicity 
was <50% at 100 µM vs. mammalian cells; ***nd, not determined; #sulfonyl derivative of the TCZ active 
metabolite ##Supporting video.
Figure 2. Optical microscopy (40×) photo of an NEJ from F. hepatica treated with compound 187 at 5 µM at 0 
and 4 hours of incubation (supporting video).
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mammalian cells: when the IC50 vs. the parasite was at least 10 times less than the IC50 vs. the mammalian cells, we 
considered these compounds as non-toxic (NT); if not, they were classified as toxic (T) (Table 2).
Then we tested the biological activity of compound 187 against the adult form of F. hepatica and S. mansoni. 
This compound was selected as it was the most potent and least toxic of our compounds and is active against the 
juvenile stages of F. hepatica. In the case of F. hepatica, parasites were affected in the first 4 h at 10 µM (Fig. 2), 
ultimately leading to the death of all the parasites after 24 h. The S. mansoni parasite was also susceptible to com-
pound 187, showing decreased motility and loss of their ventral sucker adherence to the plate floor after 24 h at 
only 5 µM.
Furthermore, the ability/potency of compound 187 to protect animals from F. hepatica infection was evalu-
ated. To this end, BALB/c mice were infected with 10 F. hepatica metacercariae and one week later, compound 187 
or TCZ were inoculated orogastrically. Compound 187, together with TCZ, protected mice from the infection 
since they presented less severe clinical signs, including a decrease in liver necrosis, hemorrhage and splenomeg-
aly (Fig. 3A). Then the transaminase profile was according to a healthy liver (Fig. 3B).
Finally, to get toxicological information about compound 187, we performed acute oral toxicology 
(up-and-down experiment), which demonstrated an LD50 of ≥2000 mg/kg body weight in mice. An in silico 
exploration of the pharmacokinetic properties of compound 187 compared to the drug-likeness of other drugs 
gave parameters similar to those of the reference drug TCZ (Supplementary Fig. 2S).
Crystal structure of FhTIM and prediction of compounds binding sites. To elucidate the molecular 
basis of FhTIM inhibition, we obtained the crystal structure of FhTIM at 1.9 Å resolution. The asymmetric unit 
displays three FhTIM dimers (Fig. 4A). Each protomer shows a typical (β/α)8 TIM-barrel fold. The R.M.S.D. 
between FhTIM and human TIM (HsTIM, PDB ID: 4POC)23 protomers is 4.5 Å on all Cα pairs, in spite of only 
a 68% sequence homology. The catalytic pocket of each protomer in the FhTIM structure is occupied by a sulfate 
molecule (SO42−), likely from the crystallization buffer. The β/α loop 6 (residues 168–180 of FhTIM) is known to 
open and close when accommodating the substrate in triosephosphate isomerases. Here, the loops are in the close 
conformation in all of the protomers of FhTIM (Fig. 4B). Interestingly, the SO42− ion is located in the same posi-
tion as the phosphate group of the substrates (glyceraldehyde 3 P) in the P. falciparum (Pf TIM) or S. aureus TIM 
structures (PDB ID: 1LYX15 and 3UWU24, respectively) through similar interactions (Fig. 4C). Indeed, the three 
unbound oxygen atoms of the O4 tetrahedron in the triose phosphate moiety of Pf TIM interact with the main 
chain nitrogen of residues G175, S211, G236 and G237, as do 3 out of 4 oxygen atoms of the FhTIM SO42−. The 
remaining oxygen of the SO42− present in the FhTIM structure (and spatially corresponding to the oxygen atom 
linking the phosphate to the sugar in the natural substrate) is coordinated by a water molecule roughly located at 
the position of the distal carbon of the substrate analog in Pf TIM (Fig. 4C). This suggests that the O4 tetrahedron 
drives the orientation of the substrate in the catalytic pocket.
Attempts to understand the mechanism of interaction between the inhibitors and TIM via crystallization did not 
yield ligand-bound structures. Thus, we used the crystal structure obtained for FhTIM to perform docking studies 
with our compounds. For each compound, we performed 10 docking calculations including the 10 best poses, 
i.e., 100 positions selected per compound, which were then clustered and ranked. For each compound, the 10 best 
positions out of these resulting datasets are included in the supporting material. Docking was performed using four 
different strategies: “blind” docking on the whole surface of FhTIM in the dimeric and the monomeric form, as well 
as targeted docking of only the active site with and without the flexibility of the residues in the active site pocket.
No preferential binding sites of the compounds could be identified on the surface of the dimer (Supplementary 
Material Fig. 1S). However, on the surface of the monomer, the compounds with the best IC50 in Table 1, includ-
ing the anti-F. hepatica drug, TCZ, bind mostly to one region, which is directly involved in the dimerization 
(Fig. 5 and Supplementary Material Fig. 1S) with predicted affinities in the micromolar range. Given the size 
of the dimeric interface, these affinities would probably not be sufficient to disrupt a pre-formed dimer but the 
compounds might impair the dimerization of monomers or result in a modification of the dimer conformation. 
Noteworthy, compounds docked on the dimeric interface are predicted to bind close to crucial residues for TIM 
Figure 3. (A) Treatment of infected mice with one dose (100 mg/kg) of 187, TCZ and as a control a lipidic 
emulsion (vehicle), (*p < 0.05). The “Clinic Score” is detailed in the methods section. (B) Transaminase profile 
at the end of the experiment.
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function. Indeed, the three representative compounds (1278, 110 and 187) are located in close contact of K14 
(less than 4 Å), and of these, 187 and 1278 (TCZ) are also predicted to interact with residue H96 (Fig. 5C,E,G). 
Both K14 and H96 are directly involved in the interaction of TIM with its natural substrate. Thus, the compounds, 
Figure 4. (A) Top (left) and side (right) view of the content of the asymmetric unit of FhTIM crystal. Dimer 
A-D: blue tints; dimer B-C: green tints; dimer E-F: yellow tints, with one SO42− molecule (green and yellow) 
per protomer. Black rectangle highlights the dimer shown in B; (B) Close-up view of dimer A-D with the two 
SO42− molecules in the active site of each monomer (red and green). Red rectangle highlights the active site of 
FhTIM shown in (C), left panel; (C) Close-up comparison of the active site of chain A of FhTIM (left panel) with 
the active site of chain A of PfTIM (PDB ID: 1LYX, right panel) with their liganded SO42− and phosphoglycolate 
(PGA), respectively. Dashed lines display the hydrogen bonds network of the ligand with neighboring 
residues/water molecules. The red sphere in the left panel corresponds to water molecule 465 of FhTIM, 
chain A. Coloring scheme for the ligands’ atoms is: red = oxygen, yellow = phosphorus, green = sulfur, light 
gray = carbon, orange = chloride. The structure of FhTIM is available in the PDB database (accession ID: 6R8H).
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although not predicted to bind the active site, could inhibit interaction of TIM with its substrate. Anyhow, the 
docking experiments place the inactivators on a location of the dimer where they could have several effects on 
TIM function, which now need to be confirmed experimentally.
Figure 5. (A) Display of the best solutions for each compound after docking with compounds 110, 187 and 
TCZ on the monomeric form of FhTIM. The position of the second monomer in the dimer is displayed as a 
ghost to show the location of the docked compounds compared to the dimeric interface. Best solution after 
docking of compounds 110 (B,C), 187 (D,E) and TCZ (F,G) on the FhTIM monomer. (B,D,F): Overall view of 
the position of the compounds. (C,E,G): close-up views of the position of the compounds with a display of the 
neighboring residues for which at least one atom lies within 4 Å of the ligand. These views are rotated 90° around 
the y-axis compared to panels B, D and F for the sake of clarity. The ligand coloring scheme is similar to Fig. 4C.
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Discussion
We discovered eleven small molecules belonging to four chemical classes (curcuminoids, thiadiazines, thio-
semicarbazides and sulfones) that inhibit recombinant FhTIM. This is the first report of inactivators on this 
enzyme. Interestingly, we found that TCZ, the reference drug in the treatment of fasciolosis, inhibits FhTIM. 
TCZ’s mechanism of action is still debated. It has been suggested that TCZ destabilizes β-tubulin25, however, the 
direct evidence for interaction has not been demonstrated and the mechanism by which the parasites develop 
TCZ resistance does not appear to be the mutation of tubulin genes25,26. The hypothesis that TCZ interacts with 
tubulin is based on the better-known mode of action of other benzimidazoles for which tubulin interaction has 
been demonstrated in antiparasitic and anticancer applications27. The evidence for TCZ/tubulin interaction is 
weak and the structure of TCZ, in any case, is different from other anti-parasitic benzimidazoles28. Our findings 
open the possibility of exploring TIM as a biological target of this drug.
Solving the first crystal structure of FhTIM provided insights both on the enzyme’s binding to natural sub-
strates in the active site and the specific mechanism of action of our inactivators. Concerning the binding of 
substrate, the presence of a sulfate ion in the active site, and the fact that is orientated and coordinated as is the 
phosphate moiety of the substrate analog in Pf TIM11, suggests that the O4 tetrahedron is important for the cor-
rect orientation and coordination of the TIM substrate. Moreover, our finding of similar interactions between 
the SO42− and the phosphate moieties of the natural substrate in the active site could explain why sulfate ions 
inhibited Trypanosoma TIM13,29 in vitro and may facilitate orienting drug-design efforts focused on sulfated/
phosphorylated molecules.
Docking suggests that the efficient FhTIM inactivators (187, 110, 116, 128), including TCZ, bind tightly at the 
enzyme’s dimerization interface (Fig. 5). As this dimerization is necessary for TIM function, our data suggest that 
our compounds could inhibit TIM by modifying or blocking the interface of the dimer. Inhibitors of protein:pro-
tein interactions have been sought for more than thirty years19 and although our compounds are small compared 
to the TIM interface, previous examples of small molecules inhibiting protein assembly have been described30. 
Moreover, in our case, as the catalytic site is at the dimeric interface, a disturbance of the topology of the interface, 
even if not leading to the disassembly of the dimer, could be sufficient to inhibit TIM function. Also, we describe 
using dynamic studies for T. cruzi TIM a particular movement in solution in the same region that allows strong 
interactions in small molecules like 18731. Then, a conformational change near the active site, could affect the 
correct substrate interaction in the active site. In particular, according to our docking results, the region of the 
dimeric interface putatively targeted by TCZ and our compounds are also close to residues K14 and H96, which 
are directly involved in the interaction of TIM with its natural substrate. Thus, 187 and TCZ may inhibit the 
binding of TIM to its substrate by blocking the catalytic loop in the closed, unfavorable conformation. Given the 
vicinity of the two zones, one cannot exclude that these two effects are involved in the inhibition by compounds 
187 and TCZ. Such a dual effect would be very interesting from a pharmaceutical point of view, as the parasites 
would need to accumulate mutations against these two effects in order to become resistant to the treatment. Our 
docking data are in silico predictions, but they warrant further experiments to seek for a functional confirmation 
of the molecular mechanisms of inhibition by compounds 187 and TCZ.
The best FhTIM inactivators are lethal to both juvenile and adult forms of F. hepatica, essentially immobilizing 
both developmental forms at 10 µM after 4 h, a significant improvement over the activity of TCZ against both 
forms (the effect of TCZ was at 48 h at more than 50 µM). Because TIMs are conserved proteins, including among 
trematodes8,31, we demonstrated that the best FhTIM inactivator compounds were also active against somules 
and adults of the S. mansoni bloodfluke. Of these, 144, 1134 and 187, were non-toxic to mammalian cells both 
herein, and previously at 100 µM against murine macrophages and human peripheral blood mononuclear cells32. 
They were also more active against both parasites than the reference drug TCZ and its active metabolite 1293 
(6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfonyl)-1H-benzo[d]imidazole). The biological activity of 187 
was observed immediately and developed faster than the other compounds. By contrast, it took several hours for 
TCZ to kill Fasciola NEJ in vitro. In addition, 187 displayed low toxicity in the acute oral toxicity assay. Moreover, 
its pharmacokinetic profile is comparable with commercially available drugs. This compound is also a moder-
ate inhibitor of thioredoxin glutathione reductase (an essential core enzyme for redox homeostasis in flatworm 
parasites) and showed effect on NEJ and Echinococcus granulosus protoscolex at 48 h and a fixed dose of 20 µM32. 
Also compound 187 protect mice infected with F. hepatica like the reference drug. We identified compound 187 
as a lead candidate and obtained FhTIM structure at 1.9 Å resolution crystals to understand the compound’s 
ligand-binding characteristics. Compound 187 is the first, selective, anthelmintic TIM inactivator reported with 
in vivo efficacy. Altogether, our findings suggest that compound 187 is a good drug candidate for the treatment 
of flatworm infections. As these zoonotic parasites affect human and animal health, our compound 187 seems a 
good lead to developing a new class of “all-in-one” drugs with broad anti-parasitic potential.
Methods
Chemicals. The studied compounds were selected from our chemo library (LIDENSA) using the following 
criteria: (i) agents belonging to T. cruzi TIM inhibitors, or/and (ii) symmetrical and benzo-containing agents, 
structurally related to previously described TIM inhibitors. The selected compounds belong to fourteen chem-
otypes: 1-thiazoles, 2-thiadiazoles, 3-quinoxalines, 4-thiosemicarbazides, 5-steroids, 6-thiadiazines and precur-
sors, 7-selenocompounds, 8-hydrazines, 9-curcuminoids, 10-indazoles, 11-imidazoles, 12-benzo-furoxanes, 
13-triazines, 14-phenazine and 40 molecules with diverse structures not clustered in any family. The purity of 
the compound was checked only with the active molecules, reaching more than 98% by HPLC-MS. The syn-
thetic procedures for the selected active compounds were described previously compound 18733, thiadiazine 
compounds34, compound 48235. Compound 1278 is TCZ, which is a commercially available anti-fascioliasis drug 
(batch PS059349, 98.9% pure from Andres Pintaluba S.A.)
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Microscale thermophoresis. MST experiments were performed according to the NanoTemper technolo-
gies protocol in a Monolith NT.115 (red/blue) instrument (NanoTemper Technologies, München, Germany36). 
With this technique, the diffusion behavior of a labeled protein is measured when an infrared light excites 
the movement of the protein in capillaries. This behavior is the combination of two effects: the fast, local 
environment-dependent responses of the fluorophore to the temperature jump and the slower diffusive thermo-
phoresis fluorescence changes. It will be modified when the protein is complexed with increasing amounts of 
unlabeled partners, leading to titration curves that can be fit for Kd estimation36. In practice, FhTIM was labeled 
with the Monolith His-Tag Labeling Kit RED-tris-NTA (NanoTemper Technologies, München, Germany), as 
described by the manufacturer. The experiments were performed using 20% and 40% MST power and between 
20–80% LED power at 24 °C. The MST traces were recorded using the standard parameters: 5 s MST power off, 
30 s MST power on, and 5 s MST power off. The compounds were used at high concentrations (around 5 mM) in 
the bindings check assay with DMSO at 5% v/v. If the binding check was positive, then the affinity determination 
was performed with the same experimental settings, with serial 2x dilutions of the compound of interest.
Inhibition of Triosephosphate Isomerase. Expression and purification of proteins: FhTIM, RabbitTIM 
and HsTIM were expressed in Escherichia coli and purified as described in the literature31,37. After purification, 
the enzyme, dissolved in 100 mM triethanolamine, 10 mM EDTA and 1 mM dithiothreitol (pH 8), was precipi-
tated with ammonium sulfate (75% saturation) and stored at 4 °C. Before use, extensive dialysis against 100 mM 
triethanolamine/10 mM EDTA (pH 7.4) was performed. Protein concentration was determined by absorbance at 
280 nm for FhTIM (ε = 33,460 M−1cm−1) and for RabbitTIM and HsTIM (ε = 33,460 M−1cm−1). Enzymatic activ-
ity was determined following the conversion of glyceraldehydes-3-phosphate into dihydroxyacetone phosphate in 
a coupled enzyme assay. The decrease in absorbance at 340 nm was followed in a multiplate reader VarioskanTM 
Flash Multimode Reader (Thermo ScientificTM, Waltham, MA, USA) at 38 °C. The reaction mixture (1 mL, pH 
7.4) contained 100 mM triethanolamine, 10 mM EDTA, 0.2 mM NADH, 1 mM glyceraldehydes-3-phosphate and 
0.9 units of α-glycerol phosphate dehydrogenase. The reaction was initiated by the addition of 5 ng/mL of the 
TIM of interest. For the inhibition studies, TIM was incubated at a concentration of 5 mg/mL in a buffer con-
taining 100 mM triethanolamine, 10 mM EDTA, pH 7.4 and 10% of DMSO at 37 °C for 1 h. The mixture also 
contained the compounds, dissolved in DMSO, at the indicated concentrations. After 1 h, 10 µL were withdrawn 
and added to a final volume of 100 µL of the reaction mixture for the activity assay. The inhibition assay was per-
formed in a 96-well microplate. None of the molecules tested here affected the activity of α-glycerol phosphate 
dehydrogenase, the enzyme used in the coupled assay. The IC50 value was taken as the concentration of drug 
needed to reduce the enzymatic activity to 50% by analysis using OriginLab8.5® sigmoidal regression (% of enzy-
matic activity vs. the logarithm of the compound concentration). The experiments were performed in triplicate 
in two independent experiments.
FhTIM crystallization. FhTIM was resuspended at 30 mg/mL in 100 mM triethanolamine/10 mM EDTA 
(pH 7.4) and stored at −80 °C until use. Protein and crystallization conditions were equilibrated at 19 °C 
for two hours before preparing the drops. The screening was performed in 96-wells plates using a Mosquito 
Nanopipetter (TTP Labtech) and commercial screens (Hampton Research, Qiagen) with the sitting drop 
method, at 19 °C in a Rockimager crystal farm (Formulatrix). Hits grew within 2 weeks in condition B2 of 
the PEGs II screen (Qiagen). Bigger crystals were grown using the hanging drop method by mixing 1 to 2 µL 
of protein solution with an equal amount of crystallization condition (0.1 M MES pH 6.5, 0.01 M ZnSO4, 50% 
PEG550mme). Crystals appeared within two weeks and were directly snap-frozen in liquid nitrogen before 
being submitted to X-ray diffraction.
X-ray data collection and structure determination. X-ray data were collected at 1.9 Å on beam-
line ID23-1 from European Synchrotron Radiation Facility, Grenoble, France at 100 K using wavelength 
λ = 0.97242 Å. Data were processed in space group P31 with cell dimensions a = b = 87.4 Å c = 186.6 Å, 
α = β = 90° and γ = 120°. Indexation and scaling were performed using XDS and XSCALE programs38. 
Molecular replacement was performed with the Phaser software39 and using the A chain of Chicken TIM (69% 
sequence homology, PDB: 4P61)40 as a search model with 6 molecules in the asymmetric unit. Initial refinement 
was performed with Phenix41 using twin law -h-k, k, -l. Water molecules were added during Phenix refinement. 
After manual curation of the structure (manual placement of the β/α loop 6 (residues 168–180), manual addi-
tion of 6 molecules of SO4, tidying up water molecules) using WinCoot42, further refinements were performed 
using Refmac 5.8.0238 from the CCP4 suite43. The structure was refined to a final Rwork of 19.6% and Rfree of 
22.4%, respectively. Statistics of the X-ray data are shown in Table 3. Geometry analysis using Rampage44 showed 
96% of the residues in preferred regions, 3.6% in allowed regions, and 6 residues (0.4%) as Ramachandran out-
liers (residues 102 and 156 from chain B, E and F).
Docking. The present crystal structure of FhTIM was used as a target in the subsequent docking studies. 
Compounds were modeled using their SMILES codes from the Chemoffice software. Then, both target protein 
and ligands were prepared using AutoDockTools v1.5.645: the polar hydrogen atoms were added, the non-polar 
hydrogens were merged, and the Gasteiger partial atomic charges were calculated. Finally, all the possible rotat-
able bonds were assigned for each compound. Four distinct docking experiments were then carried out with the 
program AutoDock Vina v1.1.246: a search on the entire surface of FhTIM in its dimeric and monomeric forms 
as well as a targeted docking in the active site only, with and without flexibility of the side chains of the residues 
defining the binding pocket. Compounds were treated as fully flexible in each experiment. The search grid was 
defined accordingly in order to encompass the considered areas. A visual examination of the resulting poses was 
performed using PyMOL (Schrödinger, Delano Scientific, LLC, New York, NY, USA).
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Cell culture. J774.1 murine macrophage cells (ATCC, USA) were grown in DMEM culture milieu contain-
ing 4 mM glutamine and supplemented with 10% FCS20. The cells were seeded in a 96-well plate (5×104 cells in 
200 µL culture medium) and incubated at 37 °C in a 5% CO2 atmosphere for 48 h, to allow cell adhesion prior 
to drug testing. Afterward, cells were exposed for 48 h to the compounds (25–400 µM) or the vehicle for con-
trol (0.4% DMSO), and additional controls (cells in medium) were used in each test. Cell viability was then 
assessed by measuring the mitochondria-dependent reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diph
enyltetrazolium bromide) to formazan. For this purpose, MTT in sterile PBS (0.2% glucose), pH 7.4, was added 
to the macrophages to achieve a final concentration of 0.1 mg/mL, and the cells were incubated at 37 °C for 3 h. 
After removing the medium, formazan crystals were dissolved in 180 µL of DMSO and 20 µL of MTT buffer 
(0.1 M glycine, 0.1 M NaCl, 0.5 mM EDTA, pH 10.5), and the absorbance at 560 nm was measured. The IC50 was 
defined as the drug concentration at which 50% of the cells were viable, relative to the control (no drug added), 
and was determined by analysis using OriginLab8.5® sigmoidal regression (% of viable cells vs. the logarithm of 
the compound concentration). Tests were performed in triplicate.
Cytotoxicity assay on bovine spermatozoa. Semen samples were obtained from a healthy fertile 
Hereford bull and kept frozen in 0.5 mL straws (extended in Andromed, Minitube, Germany47) under liquid 
nitrogen until use. The semen used belonged to a single freezing batch that was obtained during a regular col-
lection schedule with an artificial vagina. Samples from three straws were thawed and a sperm pool was pre-
pared in PBS at a concentration of 40 million spermatozoa per mL, then 50 μL of this sperm suspension was 
carefully mixed with 50 μL of compounds diluted to 100, 50, 25, 12.5 and 6.25 μM or with 1% DMSO in control 
experiments. Each condition was assayed by duplicate in 96-well plates and controls were assayed by triplicate. 
Plates were incubated at 37 °C for 1 h with moderate shaking. The motility analysis was carried out using a CASA 
(Computer Assisted Semen Analyzer) system Androvision (Minitube, Tiefenbach, Germany) with an Olympus 
BX 41 microscope (Olympus, Japan) equipped with a warm-stage at 37 °C. Each sample (10 μL) was placed onto 
a Makler Counting Chamber (depth 10 μm, Sefi-Medical Instruments, Israel) and the following parameters were 
evaluated: percentage of total motile spermatozoa (motility >5 μm/s) and velocity curved line (VCL, >24 μm/s). 
At least 400 spermatozoa were analyzed from each sample from at least four microscope fields.
In vitro NEJ treatment. F. hepatica metacercariae were acquired from DILAVE, MGAP, Uruguay. NEJ 
were obtained by in vitro excystement as previously described with minor modifications47. Briefly, metacercariae 
were incubated with 1% sodium hypochlorite for 5 min at room temperature to remove the outer cyst wall and 
then washed exhaustively with PBS 200 U/mL Penicillin G sulfate, 200 mg/mL streptomycin sulfate, 500 ng/mL 
amphotericin B, 10 mM HEPES, counted and divided into groups of around 20 parasites that were transferred to 
12 wells tissue culture plates. Parasites were maintained at 37 °C, 5% CO2 in modified Basch’s medium47. At day 
1, compounds were added at the indicated concentrations and 0.5% DMSO was added to control groups; each 
condition was tested in duplicate. NEJ behavior was monitored under a light microscope (Olympus BX41), every 
day each well was recorded for a minute in order to assess parasite motility and registered using the following 
score: 3- normally active; 2- reduced activity (sporadic movement); 1- immotile (dead)48.
Ex-vivo in the adult form of F. hepatica. F. hepatica were collected from natural infections of cattle 
obtained from Casablanca slaughterhouse in Paysandú, Uruguay49. During slaughter (500 animals observed) the 
livers that showed signs of fascioliasis (thickened canaliculi) were dissected and adult flukes were recovered and 
kept in PBS at 37 °C until used (no more than 8 h). After flukes emptied their gut content (i.e. the gut was not dark 
anymore) they were transferred to 6 well plates (one fluke per well) with 2 mL of RPMI 1640 media with 200 U/
mL Penicillin G sulfate, 200 mg/mL streptomycin sulfate, 500 ng/mL amphotericin B and 10 mM glucose at 37 °C. 
Compounds were added at a concentration of 25 µM. The antiparasitic efficacy was expressed as the percentage 
reduction of the number of flukes in the treated group compared with the control group.
Data collection FhTIM Refinement FhTIM
Space group P31 Resolution range (Å) 20-1.9
Unit cell parameters
a, b, c (Å) 87.4, 87.4, 186.6
Number of unique reflections 107970
α, β, γ (°) 90, 90, 120
Resolution range (Å) 20-1.9 (1.95-1.9) Rwork (%) 19.6
Rsym (%) 14.4 (152.5) Rfree (%) 22.4
I/σI 5.11 (0.76) Number of proteins atoms 11568
Completeness (%) 98.7 (92.9) Number of water/SO4 1116/6
Redundancy 5.15 Mean B-factor (Å2) 18.13
Coordinate deviations
RMSD bond lengths (Å) 0.01
RMSD angles (°) 1.9
PDB ID 6R8H
Table 3. Summary of X-ray data collection and refinement statistics. Values in parentheses are for the highest-
resolution shell.
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S. mansoni: treatment of somules in vitro and adults ex vivo. The NMRI isolate of S. mansoni was 
maintained by passage through Biomphalaria glabrata snails and 3–5 week-old, female Golden Syrian hamsters 
(Charles River, San Diego, CA) as intermediate and definite hosts, respectively. A dose of 600 infective larvae 
(cercariae) was used to infect hamsters. The acquisition, preparation and in vitro maintenance of S. mansoni 
post-infective larvae (schistosomula or somules) and adults have been already described5,50,51. Vertebrate animal 
maintenance and handling at the University of California San Diego Animal Care Facility were in accordance 
with protocols approved by the university’s Institutional Animal Care and Use Committee (IACUC).
Phenotypic screens with somules were performed as described5,50,51. Initially, 100 μL Basch medium52, 100 U/ml 
penicillin, 100 mg/ml streptomycin, 4% heat-inactivated FBS (Corning Mediatech) and 1 μl compound in DMSO 
were added to clear, 96-well round-bottomed plates (Costar cat.# 3367). Then, 100 μL of the same medium contain-
ing 40–50 somules was added to mix the compound with somules (final concentration of DMSO was 0.5%). Assay 
plates were placed into plastic boxes humidified with wet tissue and then incubated at 37 °C in a 5% CO2 environ-
ment. Somules phenotypes were recorded every 24 h up to 72 h using an inverted microscope (Zeiss Axiovert 40 C).
Phenotypic screens with 42-day-old, adult parasites were performed in 24-well plates (Costar cat.# 3526) con-
taining the above medium and approximately five adult males and two females per well. Compound was added 
in a volume of up to 1 μL DMSO at a concentration of 5 µM (0.05% DMSO final). Assay plates were incubated at 
37 °C in a 5% CO2 environment. Parasite phenotypes were recorded at 4, 8 and 24 h using a Zeiss Axiovert 40 C.
Schistosome phenotypic responses were recorded employing a series of ‘descriptors,’ such as rounding, degen-
eration, overactivity, loss of translucency and changes in motility, as described previously5,50,51,53. To allow for 
comparisons of compound activity, each descriptor was awarded a value of 1 and these were added up to a max-
imum ‘severity score’ of 4. Evidence of degeneracy or death was awarded the maximum score of 4. Scores were 
averaged across duplicate wells for each compound (see details in the supporting information).
Acute oral toxicity. The in vivo 50% lethal dose (LD50) was determined according to the guidelines of the 
Organization for Economic Cooperation and Development (OECD)54,55. All procedures involving animals were 
approved by the Universidad de la República’s Committee on Animal Research (CHEA Protocol ID 707). Briefly, 
healthy young adult male BALB/c mice (30 days old, 25 to 30 g) were used in this study. Initially, Compound 187 dis-
solved in vehicle was administered at 2,000 mg/kg, by orogastric cannula, to one animal. The animal was fasted, main-
tained, and observed for 14 days according to the OECD guidelines. If the mouse survived for the first 48 h, another 
animal received the same dose. If this was repeated, a third animal was dosed with 2,000 mg/kg and also observed 
for 14 days. The experiment ends at 14 days post-administration, if there are no signs of toxicity, the (LD50) is the 
administered dose, if not, the software AOT AOT425 Stat program recommendation was followed. For the vehicle 
preparation56 compound 187 was disposed in a mixture, composed of a surfactant (10%), containing Eumulgin HRE 40 
(polyoxyl-40hydrogenated castor oil), sodium oleate, and soya phosphatidylcholine (8:6:3), and an oil phase (10%) con-
taining cholesterol and phosphate buffer (pH 7.4) (80%). Compound 187 was pulverized in a mortar with cholesterol, 
Eumulgin HRE 40, and phosphatidylcholine, then the mixture was dissolved in chloroform and the solvent was evapo-
rated under vacuum to dryness. In parallel, sodium oleate was dissolved in phosphate buffer and left in an orbital shaker 
for 12 h at room temperature. The former was then added to the evaporated residue, and the mixture was homogenized 
and placed in an ultrasonic bath at full power for 30 min. The sample was kept at room temperature until use.
Mouse infection with F. hepatica. Six- to eight-week-old female BALB/c mice were obtained from DILAVE 
Laboratories57 (Uruguay). Animals were kept in the animal house (URBE, Facultad de Medicina, UdelaR, Uruguay) 
with water and food supplied ad libitum. Mouse handling and experiments were carried out in accordance with 
strict guidelines from the National Committee on Animal Research (CNEA, Uruguay). All procedures involving 
animals were approved by the Universidad de la República’s Committee on Animal Research (CHEA Protocol 
Number: 070153-000180-16). BALB/c mice were orally infected with 10 F. hepatica metacercariae per animal. 
After 1 week post-infection (wpi), mice were intragastrically inoculated with compound 187 (100 mg/kg) or TCZ 
(100 mg/kg). At 3 wpi mice were bled and sacrificed. Peritoneal exudate cells, spleens, and livers were removed 
and analyzed. In order to evaluate the severity of the infection, a disease severity score was developed (Table 3S 
Supporting Information)57, which was applied in blinded experiments. Alanine aminotransferase (ALT) activity in 
sera was determined using a commercial kit (Spinreact, Spain) according to the manufacturers’ instructions. PECs 
from infected and non-infected mice were washed twice with PBS containing 2% FBS and 0.1% sodium azide.
Ethical approval. The study was approved by the Universidad de la República’s Committee on Animal 
Research (CHEA Protocol Number: 070153-000180-16 and ID 707) Review Boards. Under the rules of Comisión 
Nacional de Experimentación Animal: (CNEA, http://www.cnea.gub.uy/).
In silico pharmacokinetic parameters. The predictions were obtained from the online free software 
SwissADME (http://www.swissadme.ch): a free web tool to evaluate pharmacokinetics, drug-likeness and medic-
inal chemistry friendliness of small molecules58. The smiles codes were provided for the software to calculate and 
the parameters.
Statistical analysis. All statistical tests were performed using Microsoft Excel. Student’s t-test (two-tailed dis-
tribution) was used to calculate P values. The number of experiments and samples was described in the figure leg-
ends. All data obtained in more than three experiments or samples show the mean ± s.d. Nonlinear least-squares 
fitting was performed using KaleidaGraph Ver. 4.5 to evaluate inhibition activity of compounds (IC50).
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